Drugs / 14C-ACT-777991
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04798209 | Jan 2021 → Jan 2022 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 14C-ACT-777991 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04798209 ↗ |
| Route | Intravenous | “Single dose of 14C-ACT-777991 microtracer, administered intravenously” NCT04798209 ↗ |